The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Open accessAbstract
HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was largely ineffective in pre-clinical and clinical settings and was therefore abandoned. However, recently developed single-cell-based antibody cloning methods have uncovered a new generation of far more potent broadly neutralizing antibodies to HIV-1 (refs 4, 5). These antibodies can prevent infection and suppress viraemia in humanized mice and nonhuman primates, but their potential for human HIV-1 immunotherapy has not been evaluated. Here we report the results of a first-in-man dose escalation phase 1 clinical trial of 3BNC117, a potent human CD4 binding site antibody, in uninfected and HIV-1-infected individuals. 3BNC117 infusion was well tolerated and demonstrated favourable pharmacokinetics. A single 30 mg kg−1 infusion of 3BNC117 reduced the viral load in HIV-1-infected individuals by 0.8–2.5 log10 and viraemia remained significantly reduced for 28 days. Emergence of resistant viral strains was variable, with some individuals remaining sensitive to 3BNC117 for a period of 28 days. We conclude that, as a single agent, 3BNC117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a new modality for HIV-1 prevention, therapy and cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., & Gascuel, O. (2010) · Systematic Biology · doi:10.1093/sysbio/syq010 · Cited by 18,376
WebLogo: A Sequence Logo Generator: Figure 1
Crooks, G. E., Hon, G., Chandonia, J.-M., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,386
Antibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
The end of AIDS: HIV infection as a chronic disease
Deeks, S. G., Lewin, S. R., & Havlir, D. V. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61809-7 · Cited by 2,063
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
Study, T. I. H. C. (2010) · Science · doi:10.1126/science.1195271 · Cited by 1,171
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y. K., Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011) · Science · doi:10.1126/science.1207227 · Cited by 1,139
Self-citationLi, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S., Velinzon, K., Pietzsch, J., Ott, R. G., Anthony, R. M., Zebroski, H., Hurley, A., et al. (2009) · Nature · doi:10.1038/nature07930 · Cited by 867
Self-citationDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
Barouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644
Self-citationSalazar-Gonzalez, J. F., Bailes, E., Pham, K. T., Salazar, M. G., Guffey, M. B., Keele, B. F., Derdeyn, C. A., Farmer, P., Hunter, E., Allen, S., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02660-07 · Cited by 596
Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays
Montefiori, D. C. (2004) · Current Protocols in Immunology · doi:10.1002/0471142735.im1211s64 · Cited by 580
Antibody-based protection against HIV infection by vectored immunoprophylaxis
Balazs, A. B., Chen, J., Hong, C. M., Rao, D. S., Yang, L., & Baltimore, D. (2012) · Nature · doi:10.1038/nature10660 · Cited by 545
Klein, F., Diskin, R., Scheid, J. F., Gaebler, C., Mouquet, H., Georgiev, I. S., Pancera, M., Zhou, T., Incesu, R.-B., Fu, B. Z., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.018 · Cited by 537
Self-citationTrkola, A., Kuster, H., Rusert, P., Joos, B., Fischer, M., Leemann, C., Manrique, A., Huber, M., Rehr, M., Oxenius, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1244 · Cited by 502
HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
Klein, F., Halper-Stromberg, A., Horwitz, J. A., Gruell, H., Scheid, J. F., Bournazos, S., Mouquet, H., Spatz, L. A., Diskin, R., Abadir, A., et al. (2012) · Nature · doi:10.1038/nature11604 · Cited by 500
Self-citationBroadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2014) · Cell · doi:10.1016/j.cell.2014.08.023 · Cited by 493
Self-citationMoldt, B., Rakasz, E. G., Schultz, N., Chan-Hui, P.-Y., Swiderek, K., Weisgrau, K. L., Piaskowski, S. M., Bergman, Z., Watkins, D. I., Poignard, P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214785109 · Cited by 463
Antibodies in HIV-1 Vaccine Development and Therapy
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J. F., Scharf, L., & Nussenzweig, M. C. (2013) · Science · doi:10.1126/science.1241144 · Cited by 457
Self-citationAntibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O. K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M., Lifson, J. D., et al. (2013) · Nature · doi:10.1038/nature12746 · Cited by 455
Self-citationHalper-Stromberg, A., Lu, C.-L., Klein, F., Horwitz, J. A., Bournazos, S., Nogueira, L., Eisenreich, T. R., Liu, C., Gazumyan, A., Schaefer, U., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.043 · Cited by 381
Self-citationIncreasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design
Diskin, R., Scheid, J. F., Marcovecchio, P. M., West, A. P., Klein, F., Gao, H., Gnanapragasam, P. N. P., Abadir, A., Seaman, M. S., Nussenzweig, M. C., et al. (2011) · Science · doi:10.1126/science.1213782 · Cited by 375
Self-citationZhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., Georgiev, I. S., Altae-Tran, H. R., Chuang, G.-Y., Joyce, M. G., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.04.012 · Cited by 366
Self-citationFalkowska, E., Le, K. M., Ramos, A., Doores, K. J., Lee, J. H., Blattner, C., Ramirez, A., Derking, R., van Gils, M. J., Liang, C.-H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.009 · Cited by 359
Self-citationStructural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321
Self-citationAntibody‐mediated modulation of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00910.x · Cited by 285
Horwitz, J. A., Halper-Stromberg, A., Mouquet, H., Gitlin, A. D., Tretiakova, A., Eisenreich, T. R., Malbec, M., Gravemann, S., Billerbeck, E., Dorner, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315295110 · Cited by 271
Self-citationRapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay
Laird, G. M., Eisele, E. E., Rabi, S. A., Lai, J., Chioma, S., Blankson, J. N., Siliciano, J. D., & Siliciano, R. F. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003398 · Cited by 239
Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike
Scharf, L., Scheid, J. F., Lee, J. H., West, A. P., Chen, C., Gao, H., Gnanapragasam, P. N. P., Mares, R., Seaman, M. S., Ward, A. B., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.001 · Cited by 212
Self-citationMechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 170
West, A. P., Scharf, L., Horwitz, J. A., Klein, F., Nussenzweig, M. C., & Björkman, P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309215110 · Cited by 125
Self-citationMehandru, S., Vcelar, B. A., Wrin, T., Stiegler, G. M., Joos, B., Mohri, H., Boden, D., Galovich, J., Tenner‐Racz, K., Rácz, P., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01340-07 · Cited by 120
Armbruster, C., Stiegler, G. M., Vcelar, B. A., Jäger, W. R., Köller, U., Jilch, R., Ammann, C. G., Pruenster, M., Stoiber, H., & Katinger, H. W. D. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh428 · Cited by 107
Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants
Klein, F., Nogueira, L., Nishimura, Y., Phad, G. E., West, A. P., Halper-Stromberg, A., Horwitz, J. A., Gazumyan, A., Liu, C., Eisenreich, T., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20141050 · Cited by 82
Self-citationSomsouk, M., Dunham, R. M., Cohen, M. L., Albright, R. G., Abdel‐Mohsen, M., Liegler, T. J., Lifson, J. D., Piatak, M., Gorelick, R. J., Huang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116306 · Cited by 70
Self-citationIsolation and propagation of HIV-1 on peripheral blood mononuclear cells
Wout, A. B. V. ’., Schuitemaker, H., & Kootstra, N. A. (2008) · Nature Protocols · doi:10.1038/nprot.2008.3 · Cited by 65
Cited by
Vinuesa, C. G., Linterman, M. A., Yu, D., & MacLennan, I. C. M. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055605 · Cited by 1,141
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Self-citationGünthard, H. F., Saag, M. S., Benson, C. A., del Rio, C., Eron, J. J., Gallant, J. E., Hoy, J. F., Mugavero, M. J., Sax, P. E., Thompson, M. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 656
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design
Burton, D. R., & Hangartner, L. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055515 · Cited by 583
Metadata
- Authors
- Caskey, M., Klein, F., Lorenzi, J. C. C., Seaman, M. S., West, A. P., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J. F., Horwitz, J. A., Shimeliovich, I., Ben-Avraham, S., Witmer-Pack, M., Platten, M., Lehmann, C., Burke, L. A., Hawthorne, T., Gorelick, R. J., Walker, B. D., Keler, T., Gulick, R. M., Fätkenheuer, G., Schlesinger, S. J., & Nussenzweig, M. C.
- Venue
- Nature
- Published
- 2015-04-08
- Volume
- 522
- Issue
- 7557
- Pages
- 487-491
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2038110764
- Cited by
- 767
- References
- 37
- FWCI
- 52.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.